Form 8-K - Current report:
SEC Accession No. 0001764013-25-000128
Filing Date
2025-08-11
Accepted
2025-08-11 07:14:17
Documents
13
Period of Report
2025-08-11
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K imvt-20250811.htm   iXBRL 8-K 27330
2 EX-99.1 exhibit9912025811.htm EX-99.1 95594
  Complete submission text file 0001764013-25-000128.txt   247797

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT imvt-20250811.xsd EX-101.SCH 1779
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT imvt-20250811_lab.xml EX-101.LAB 21629
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT imvt-20250811_pre.xml EX-101.PRE 12506
15 EXTRACTED XBRL INSTANCE DOCUMENT imvt-20250811_htm.xml XML 2712
Mailing Address 320 WEST 37TH STREET NEW YORK NY 10018
Business Address 320 WEST 37TH STREET NEW YORK NY 10018 917-580-3099
Immunovant, Inc. (Filer) CIK: 0001764013 (see all company filings)

EIN.: 832771572 | State of Incorp.: DE | Fiscal Year End: 0331
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)